Glycemic control in the pediatric intensive care unit of Leuven: two years of experience

Tom Van Herpe1, Koen Vanhonsebrouck, Dieter Mesotten

  • 1Department of Intensive Care Medicine, University Hospitals Leuven, Katholieke Universiteit Leuven, Leuven, Belgium. tom.vanherpe@esat.kuleuven.be

Insights

Intensive insulin therapy for tight glycemic control (TGC) in critically ill patients showed benefits in early studies but later research highlighted its complexity. This review focuses on the Leuven TGC concept, particularly in pediatric intensive care units (PICUs).

Area of Science:

  • Critical care medicine
  • Endocrinology
  • Pediatrics

Background:

  • Stress hyperglycemia and hypoglycemia increase mortality in critically ill patients.
  • Intensive insulin therapy was initially shown to improve outcomes through tight glycemic control (TGC).
  • Subsequent studies revealed complexities and challenges in replicating these findings.

Purpose of the Study:

  • To provide an overview of the methodological aspects of the Leuven TGC concept.
  • To focus on the application and considerations of TGC in pediatric intensive care units (PICUs).
  • To highlight differences between adult and PICU implementations of TGC.

Main Methods:

  • Review of three randomized controlled trials from Leuven University (surgical, medical, PICU).
  • Analysis of methodological aspects of the Leuven TGC concept.
  • Comparison of adult versus PICU approaches to TGC.

Main Results:

  • Initial Leuven studies demonstrated benefits of TGC using intensive insulin therapy.
  • Follow-up studies indicated that TGC results were not consistently confirmed.
  • Complexity in clinical practice associated with TGC was identified.

Conclusions:

  • The Leuven TGC concept involves applying intensive insulin therapy to maintain age-adjusted narrow blood glucose limits.
  • Implementing TGC, especially in PICUs, requires careful consideration of methodological details and potential complexities.
  • Understanding these aspects can assist other ICUs in implementing TGC effectively.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Diabetic Ketoacidosis l: Introduction01:25

Diabetic Ketoacidosis l: Introduction

DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...